316 related articles for article (PubMed ID: 12374285)
21. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
22. [Current concepts on apoptotic signalling pathways: new targets for anticancer strategies].
Ségal-Bendirdjian E; Hillion J; Belmokhtar CA
Bull Cancer; 2003 Jan; 90(1):9-17. PubMed ID: 12609799
[TBL] [Abstract][Full Text] [Related]
23. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
Ruiz de Almodóvar C; Ruiz-Ruiz C; Muñoz-Pinedo C; Robledo G; López-Rivas A
Oncogene; 2001 Oct; 20(48):7128-33. PubMed ID: 11704839
[TBL] [Abstract][Full Text] [Related]
24. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
25. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
26. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review).
Bonavida B; Ng CP; Jazirehi A; Schiller G; Mizutani Y
Int J Oncol; 1999 Oct; 15(4):793-802. PubMed ID: 10493964
[TBL] [Abstract][Full Text] [Related]
27. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies.
Buchner M; Brantner P; Stickel N; Prinz G; Burger M; Bär C; Dierks C; Pfeifer D; Ott A; Mertelsmann R; Gribben JG; Veelken H; Zirlik K
Br J Haematol; 2010 Oct; 151(2):167-78. PubMed ID: 20738306
[TBL] [Abstract][Full Text] [Related]
28. Regulators of apoptosis as anticancer targets.
Tolcher AW
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1255-67. PubMed ID: 12512391
[TBL] [Abstract][Full Text] [Related]
29. Immunogenic anti-cancer chemotherapy as an emerging concept.
Haynes NM; van der Most RG; Lake RA; Smyth MJ
Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
[TBL] [Abstract][Full Text] [Related]
30. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
31. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
32. Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics.
Bonavida B; Garban H
Redox Biol; 2015 Dec; 6():486-494. PubMed ID: 26432660
[TBL] [Abstract][Full Text] [Related]
33. Targeting apoptosis in prostate cancer.
DiPaola RS; Patel J; Rafi MM
Hematol Oncol Clin North Am; 2001 Jun; 15(3):509-24. PubMed ID: 11525294
[TBL] [Abstract][Full Text] [Related]
34. Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment.
Joseph B; Marchetti P; Formstecher P; Kroemer G; Lewensohn R; Zhivotovsky B
Oncogene; 2002 Jan; 21(1):65-77. PubMed ID: 11791177
[TBL] [Abstract][Full Text] [Related]
35. Death receptor ligands, in particular TRAIL, to overcome drug resistance.
de Jong S; Timmer T; Heijenbrok FJ; de Vries EG
Cancer Metastasis Rev; 2001; 20(1-2):51-6. PubMed ID: 11831647
[TBL] [Abstract][Full Text] [Related]
36. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
37. [Death inducing ligands in combination with ionizing radiation: objective and current knowledge].
Belka C; Betsch A; Marini P; Jendrossek V; Bamberg M; Budach W
Strahlenther Onkol; 2003 Mar; 179(3):141-51. PubMed ID: 12627256
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
39. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.
Schimmer AD; Thomas MP; Hurren R; Gronda M; Pellecchia M; Pond GR; Konopleva M; Gurfinkel D; Mawji IA; Brown E; Reed JC
Cancer Res; 2006 Feb; 66(4):2367-75. PubMed ID: 16489043
[TBL] [Abstract][Full Text] [Related]
40. Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer.
Maji S; Panda S; Samal SK; Shriwas O; Rath R; Pellecchia M; Emdad L; Das SK; Fisher PB; Dash R
Adv Cancer Res; 2018; 137():37-75. PubMed ID: 29405977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
